A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Key Inclusion Criteria:

• Males or non-pregnant females aged between 18 and 80 years (inclusive) at time ofsigning the informed consent form (ICF)

• Biopsy-confirmed MASH with fibrosis stage F2 or F3

• Body mass index (BMI) at screening ≥25.0 kilograms (kg)/meters squared (m^2) (≥23kg/m^2 for Asian participants).

Key Exclusion Criteria:

• Chronic liver diseases other than MASH

• Evidence of cirrhosis on screening liver biopsy

• Have type 1 diabetes or poorly controlled type 2 diabetes

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥250 units perliter (U/L)

• Participants taking vitamin E (>400 international units [IU]/day) or pioglitazonemust be on stable dose for at least 6 months prior to Screening

Other inclusion and exclusion criteria may apply.